Acute Respiratory Distress Syndrome Pipeline: Emerging Therapies and Key Pharma Players Involved by DelveInsight | Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel and Others

Acute Respiratory Distress Syndrome Pipeline

Acute Respiratory Distress Syndrome (ARDS) Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome (ARDS) market. A detailed picture of the Acute Respiratory Distress Syndrome (ARDS) pipeline landscape is provided, which includes the disease overview and Acute Respiratory Distress Syndrome (ARDS) treatment guidelines.

The assessment part of the report embraces in-depth Acute Respiratory Distress Syndrome (ARDS) commercial assessment and clinical assessment of the Acute Respiratory Distress Syndrome (ARDS) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Respiratory Distress Syndrome (ARDS) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


The key players in Acute Respiratory Distress Syndrome market are:

Faron Pharmaceuticals
BioMarck Pharmaceuticals
Techpool Bio-Pharma
APEPTICO Forschung und Entwicklung GmbH
Apeiron Biologics/GlaxoSmithKline
Implicit Bioscience
United Therapeutics


Request for Sample Page:


Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.

The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.


Request for Sample Page:


The launch of the emerging therapies is expected to significantly impact Acute Respiratory Distress Syndrome treatment scenario in the upcoming years:-

Acute Respiratory Distress Syndrome Drugs covered:

Solnatide (AP301)
APN01 (GSK2586881)
Remodulin (Treprostinil Inhalation Solution)


Request for Sample Page:


Acute Respiratory Distress Syndrome (ARDS) Analytical Perspective by DelveInsight

In-depth Acute Respiratory Distress Syndrome (ARDS) Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Acute Respiratory Distress Syndrome (ARDS) Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.


Scope of the Acute Respiratory Distress Syndrome report

The Acute Respiratory Distress Syndrome (ARDS) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Acute Respiratory Distress Syndrome (ARDS) across the complete product development cycle, including all clinical and nonclinical stages.
It comprises of detailed profiles of Acute Respiratory Distress Syndrome (ARDS) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
Detailed Acute Respiratory Distress Syndrome (ARDS) research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Acute Respiratory Distress Syndrome (ARDS).


Acute Respiratory Distress Syndrome Key Questions

What are the current options for Acute Respiratory Distress Syndrome (ARDS) treatment?
How many companies are developing therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)? 
What are the principal therapies developed by these companies in the industry?
How many therapies are developed by each company for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
How many Acute Respiratory Distress Syndrome (ARDS) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Acute Respiratory Distress Syndrome (ARDS) market? 
Which are the dormant and discontinued products and the reasons for the same?
What is the unmet need for current therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?  
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Acute Respiratory Distress Syndrome (ARDS) therapies? 
What are the clinical studies going on for Acute Respiratory Distress Syndrome (ARDS) and their status?
What are the results of the clinical studies and their safety and efficacy? 
What are the key designations that have been granted for the emerging therapies for Acute Respiratory Distress Syndrome (ARDS)? 
How many patents are granted and pending for the emerging therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)? 


Request for Sample Page:


Table of Contents:       

1. Report Introduction

2. Acute Respiratory Distress Syndrome (ARDS) 

3. Acute Respiratory Distress Syndrome (ARDS) Current Treatment Patterns

4. Acute Respiratory Distress Syndrome (ARDS) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Acute Respiratory Distress Syndrome (ARDS) Late Stage Products (Phase-III)

7. Acute Respiratory Distress Syndrome (ARDS) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Respiratory Distress Syndrome (ARDS) Discontinued Products

13. Acute Respiratory Distress Syndrome (ARDS) Product Profiles

14. Acute Respiratory Distress Syndrome (ARDS) Key Companies

15. Acute Respiratory Distress Syndrome (ARDS) Key Products

16. Dormant and Discontinued Products

17. Acute Respiratory Distress Syndrome (ARDS) Unmet Needs

18. Acute Respiratory Distress Syndrome (ARDS) Future Perspectives

19. Acute Respiratory Distress Syndrome (ARDS) Analyst Review  

20. Appendix

21. Report Methodology


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Are you a market researcher?

Explore our research partnership options.


Find out what people like and dislike about your competitors, and compare it with your brand performance.

Competitor Analyzer

Generated by Feedzy
%d bloggers like this: